Compare United States Natural Gas Fund (UNG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Natural Gas Fund vs State Street SPDR S&P Biotech ETF — how do they compare? United States Natural Gas Fund trades at $11.01 (market cap $517.27M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 19.5× United States Natural Gas Fund's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Natural Gas Fund for 22 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UNG | XBI | |
|---|---|---|
Market Cap | $517.27M | $10.11B |
Volume | 29,485,537 | 12,903,266 |
Sector | Commodities - Energy | Broad Market / Factor |
52-Week High | $16.90 | $169.55 |
52-Week Low | $9.63 | $104.99 |
Typical Hold Time | 22 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UNG trades at $10.81, down 1.99% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong net income of $65.15M for 2024 despite zero revenue, with robust cash flow from operations of $47.54M. Recent news highlights natural gas market volatility driven by record production and geopolitical tensions.
The outlook is mixed: technical momentum supports near-term upside, but fundamental concerns arise from zero revenue and negative net cash flow. Risks include commodity price sensitivity and geopolitical factors affecting natural gas markets. Analyst sentiment leans bullish on technicals but requires fundamental improvement for sustained growth.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
